Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Ocugen, Inc. reported transformative developments in 2025, including advancements in gene therapy programs, licensing agreements, and leadership appointments, positioning the company for future growth and BLA filings [2][9] Financial Performance - For Q4 2025, research and development expenses were $10.7 million, up from $8.3 million in Q4 2024, while general and administrative expenses slightly decreased to $6.1 million from $6.3 million [15] - The net loss per common share for Q4 2025 was $0.06, compared to a loss of $0.05 in Q4 2024 [15] - For the full year 2025, research and development expenses totaled $39.8 million, an increase from $32.1 million in 2024, and the net loss per common share was $0.23, compared to $0.20 in 2024 [15] Clinical Trials and Developments - Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa is complete, with topline data expected in Q1 2027, supporting a potential BLA filing [2][4] - The OCU410ST Phase 2/3 GARDian clinical trial for Stargardt disease is ahead of schedule, with interim data expected in Q3 2026 [3][11] - Preliminary data from the Phase 2 ArMaDa clinical trial for OCU410 showed a 46% reduction in lesion growth at 12 months, indicating potential effectiveness in treating geographic atrophy [4][5] Market Opportunities - OCU410 targets a significant market with approximately 2 to 3 million geographic atrophy patients in the U.S. and Europe, addressing a critical unmet medical need [7] - The licensing agreement with Kwangdong Pharmaceutical for OCU400's rights in Korea is part of a strategic partnership approach, enhancing Ocugen's business development strategy [7] Cash Position and Funding - As of December 31, 2025, Ocugen had $18.9 million in cash and restricted cash, down from $58.8 million in 2024, with additional funding secured through a $22.5 million offering in January 2026 [15][8] - The company anticipates that the proceeds from recent financing will extend its cash runway into Q4 2026, potentially into Q2 2027 if warrants are exercised [15][8]